|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Profiles and removal efficiency of polycyclic aromatic hydrocarbons by two different types of sewage treatment plants in Hong Kong显示文摘Sewage discharge could be a major source of polycyclic aromatic hydrocarbons(PAHs) in the coastal waters. Stonecutters Island and Shatin Sewage Treatment Works(SCISTW and STSTW)in Hong Kong, adopted chemically enhanced primary treatment and biological treatment,respectively. This study aimed at(1) determining the removal efficiencies of PAHs,(2) comparing the capabilities in removing PAHs, and(3) characterizing the profile of each individual PAHs, in the two sewage treatment plants(STPs). Quantification of 16 PAHs was conducted by a Gas Chromatography. The concentrations of total PAHs decreased gradually along the treatment processes(from 301 ± 255 and 307 ± 217 ng/L to 14.9 ± 12.1 and 63.3 ± 54.1 ng/L in STSTW and SCISTW, respectively). It was noted that STSTW was more capable in removing total PAHs than SCISTW with average total removal efficiency 94.4% ± 4.12% vs. 79.2% ± 7.48%(p < 0.05). The removal of PAHs was probably due to sorption in particular matter, confirmed by the higher distribution coefficient of individual and total PAHs in solid samples(dewatered sludge contained92.5% and 74.7% of total PAHs in SCISTW and STSTW, respectively) than liquid samples(final effluent-total contained 7.53% and 25.3% of total PAHs in STSTW and SCISTW, respectively).Despite the impressive capability of STSTW and SCISTW in removing PAHs, there was still a considerable amount of total PAHs(1.85 and 39.3 kg/year, respectively for the two STPs) being discharged into Hong Kong coastal waters, which would be an environmental concern. | Yu Bon Man Ka Lai Chow Zhang Cheng Wing Yin Mo Yung Hau Chan James Chung Wah Lam Frankie Tat Kwong Lau Wing Cheong Fung Ming Hung Wong | 2017 | Journal of Environmental Sciences2017，29，3： | 5 |
| 2 | International validation of the Chinese University Prognostic Index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study显示文摘The outcome of hepatocellular carcinoma(HCC) patients significantly differs between western and eastern population centers. Our group previously developed and validated the Chinese University Prognostic Index(CUPI) for the prognostication of HCC among the Asian HCC patient population. In the current study, we aimed to validate the CUPI using an international cohort of patients with HCC and to compare the CUPI to two widely used staging systems, the Barcelona Clinic Liver Cancer(BCLC) classification and the Cancer of the Liver Italian Program(CLIP). To accomplish this goal, two cohorts of patients were enrolled in the United Kingdom(UK; n = 567; 2006-2011) and Hong Kong(HK; n = 517; 2007-2012). The baseline clinical data were recorded. The performances of the CUPI, BCLC, and CLIP were compared in terms of a concordance index(C-index) and were evaluated in subgroups of patients according to treatment intent. The results revealed that the median follow-up durations of the UK and HK cohorts were 27.9 and 29.8 months, respectively. The median overall survival of the UK and HK cohorts were 22.9 and 8.6 months, respectively. The CUPI stratified the patients in both cohorts into three risk subgroups corresponding to distinct outcomes. The median overall survival of the CUPI low-, intermediate-, and high-risk subgroups were 3.15, 1.24, and 0.29 years, respectively, in the UK cohort and were 2.07, 0.32, and 0.10 years, respectively, in the HK cohort. For the patients who underwent curative treatment, the prognostic performance did not differ between the three staging systems, and all were suboptimal. For those who underwent palliative treatment, the CUPI displayed the highest C-index, indicating that this staging system was the most informative for both cohorts. In conclusion, the CUPI is applicable to both western and eastern HCC patient populations. The performances of the three staging systems differed according to treatment intent, and the CUPI was demonstrated to be optimal for those undergoing palliative treatment. A more precise staging system for early-stage disease patients is required. | Stephen L.Chan Philip J.Johnson Frankie Mo Sarah Berhane Mabel Teng Anthony W.H.Chan Ming C.Poon Paul B.S.Lai Simon Yu Anthony T.C.Chan Winnie Yeo | 2014 | Chinese Journal of Cancer2014，33，10： | 4 |
| 3 | A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma显示文摘 | Stephen L. Chan Frankie K. F. Mo Cesar S. C. Wong Charles M. L. Chan Linda K. S. Leung Edwin P. Hui Brigette B. Ma Anthony T. C. Chan Tony S. K. Mok Winnie Yeo | 2011 | Cancer2011，，16： | 2 |
| 4 | Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma显示文摘 | Herbert H. Loong Brigette B.Y. Ma Sing-Fai Leung Frankie Mo Edwin P. Hui Michael K. Kam Stephen L. Chan Brian K.H. Yu Anthony T.C. Chan | 2012 | Radiotherapy and Oncology2012，，3： | 1 |
| 5 | Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma显示文摘 | Herbert H. Loong Brigette B.Y. Ma Sing-Fai Leung Frankie Mo Edwin P. Hui Michael K. Kam Stephen L. Chan Brian K.H. Yu Anthony T.C. Chan | 2012 | Radiotherapy and Oncology2012，，3： | 1 |
| 6 | Identification of optimal contemporary antiemetic prophylaxis for doxorubicin-cyclophosphamide chemotherapy in Chinese cancer patients: post-hoc analysis of 3 prospective studies显示文摘Objective:Chemotherapy-induced nausea and vomiting(CINV)are common with doxorubicin-cyclophosphamide(AC)chemotherapy.Recommended antiemetic regimens incorporate neurokinin-1 receptor antagonist(NK1 RA),5-hydroxytryptamine type-3 receptor antagonist(5 HT3 RA),corticosteroid,and dopamine antagonists.This post-hoc analysis compared results of 3 prospective antiemetic studies conducted among Chinese breast cancer patients who received(neo)adjuvant AC,in order to identify optimal antiemetic prophylaxis.Methods:A total of 304 patients were included:Group 1,ondansetron/dexamethasone(D1);Group 2,aprepitant/ondansetron/dexamethasone(D1);Group 3,aprepitant/ondansetron/dexamethasone(D1–3);Group 4,aprepitant/ondansetron/dexamethasone(D1–3)/olanzapine;and Group 5,netupitant/palonosetron/dexamethasone(D1–3).Antiemetic efficacies of Groups 3,4,and 5 during cycle 1 of AC were individually compared with Group 1.In addition,emesis outcomes of patients in Groups 3 and 5,and those of Groups 2 and 3,were compared.Results:When comparing efficacies of a historical doublet(5 HT3 RA/dexamethasone)with triplet antiemetic regimens(NK1 RA/5 HT3 RA/dexamethasone)with/without olanzapine,complete response(CR)percentages and quality of life(QOL)in overall phase of cycle 1 AC were compared between Group 1 and the other groups:Group 1 vs.3,41.9%vs.38.3%(P=0.6849);Group 1 vs.4,41.9%vs.65.0%(P=0.0107);and Group 1 vs.5,41.9%vs.60.0%(P=0.0460).Groups 4 and 5 achieved a better QOL.When comparing netupitant-based(Group 3)with aprepitant-based(Group 5)triplet antiemetics,CR percentages were 38.3%vs.60.0%,respectively(P=0.0176);Group 5 achieved a better QOL.When comparing 1 day(Group 2)vs.3 day(Group 3)dexamethasone,CR percentages were 46.8%and 38.3%,respectively(P=0.3459);Group 3 had a worse QOL.Conclusions:Aprepitant-containing triplets were non-superior to doublet antiemetics.Netupitant-containing triplets and adding olanzapine to aprepitant-containing triplets were superior to doublets.Netupitant/palonosetron/dexamethasone was superior to aprepitant/ondansetron/dexamethasone.Protracted administration of dexamethasone provided limited additional benefit. | Winnie Yeo Leung Li Thomas KH Lau Kwai T Lai Vicky,TC Chan Kwan H Wong Christopher CH Yip Elizabeth Pang Maggie Cheung Vivian Chan Carol CH Kwok Joyce JS Suen Frankie KF Mo | 2021 | Cancer Biology & Medicine2021，18，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员